Long Ideas - Incyte (NASDAQ:INCY) shares plummeted today after the company released its second quarter earnings report. Although the report showed top- and bottom-line growth, revenue generation came … Continue Reading
Read nowLong Ideas - ALK inhibitor crizotinib was approved last August under Pfizer’s (NYSE:PFE) marketing name Xalkori for the treatment of some forms of non-small cell lung cancer (NSCLC). … Continue Reading
Read now- Teva Pharmaceuticals (NASDAQ:TEVA) posted in-line Q2 earnings this morning, although TEVA is trading down 2%. With EPS of $1.28 and 19% revenue growth for the … Continue Reading
Read nowQuick Picks - With Gilead (NASDAQ:GILD) paying $11 billion for Pharmasset last year, the action around the next generation of hepatitis C treatments has centered on nucleoside type … Continue Reading
Read now- Novartis (NYSE:NVS) is gaining slowly in pre-market trading after Tuesday’s announcement that the company terminated licensing responsibilities with Idenix (NASDAQ:IDIX). NVS gapped down 5% on … Continue Reading
Read nowLong Ideas - Botox producer Allergan, Inc. (NYSE:AGN) reported its second quarter earnings today, with substantial all-around growth. Net income rose 19% from the last year to $296 … Continue Reading
Read nowLong Ideas - Navidea BioPharma (NASDAQ:NAVB) announced last night that it has entered into a licensing agreement with Alseres Pharmaceuticals (OTC:ALSE) for the development of ALSE’s Altropane imaging … Continue Reading
Read now